Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How would you approach treatment for local chest wall recurrence while on Anastrozole for a postmenopausal woman with ER+ IDC s/p mastectomy?
What systemic therapy would you use?
Related Questions
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
Would you give adjuvant TDM-1 to a patient with HER2-positive breast cancer s/p NAC with TCHP found to have no residual disease in the breast, but presence of ITCs ypN0(i+) in one axillary lymph node?
How do you respond to a patient who asks "Why do I still need breast radiation after chemotherapy if chemotherapy treats the whole body?"
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
What endocrine therapy would you recommend to a premenopausal female with early stage HR+ Breast cancer who is transitioning from female to male and currently on testosterone?
For pre or perimenopausal women with early stage, hormone positive breast cancer who refuse to stop HRT (for severe perimenopausal symptoms - severe depression/anxiety/very low energy/vaginal dryness and pain with sex that's failed vaginal estrogen therapy), do you still recommend Tamoxifen or other endocrine therapy in addition to the HRT that is being taken?
What is your treatment approach in patients with early breast cancer with axillary soft tissue involvement, with or without concurrent lymph node involvement?
Would you consider offering adjuvant Olaparib to a patient with early stage triple negative breast cancer, cT3N0, ypT1aN0, with BRCA VUS who has residual disease after neoadjuvant KEYNOTE-522 regimen?
What factors would you consider when deciding between tamoxifen vs OFS/AI in premenopausal women with early stage HR+ breast cancer?
would you recommend ALND to a postmenopausal female with one positive lymph node and small volume metastasis in other Lymph nodes?